Cabozantinib: adverse event reports filed with FDA

2,790

reports as suspect product

0% of all reports · about 207 a year

139

reports, 12 months to June 2026

201 in the 12 months before

95.4%

marked serious by the reporter

70.8% across the class

20.6%

record death among outcomes, as reported

574 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Cabozantinib reports recording the termmedian drug in kinase inhibitor

1. Diarrhoealoose or frequent stools13.5%376
2. Fatiguetiredness8.4%233
3. Malignant neoplasm progression8.3%232
4. Off label useused for a purpose or in a way not on the label7.6%211
5. Nauseafeeling sick6.7%186
6. Decreased appetitereduced appetite6.3%175
7. Hypertensionhigh blood pressure5.5%153
8. Astheniaweakness or lack of energy5.1%141
9. Vomitingbeing sick4.9%136
10. Deaththe patient died; cause not stated by this term4.8%133
11. Palmar-plantar erythrodysaesthesia syndrome4.7%131
12. Stomatitissore mouth4.4%123
13. General physical health deteriorationgeneral decline in health3.8%107
14. Weight decreasedweight loss3.7%104
15. Pyrexiafever3.7%103
16. Dyspnoeashortness of breath3.6%101
17. Pulmonary embolisma blood clot in the lung3.5%99
18. Anaemialow red blood cells3.5%97
19. Drug ineffectivethe medicine did not work as expected3.3%93
20. Abdominal painstomach or belly pain3.1%87
21. Pneumonialung infection3%84
22. Alanine aminotransferase increasedraised liver enzyme (ALT)3%83
23. Hypothyroidismunderactive thyroid2.9%82
24. Sepsisa severe body-wide response to infection2.9%80
25. Disease progressionthe disease advanced2.8%77
26. Aspartate aminotransferase increasedraised liver enzyme (AST)2.7%74
27. Acute kidney injurysudden loss of kidney function2.6%73
28. Mucosal inflammation2.4%68
29. Dehydrationdehydration2.4%66
30. Hyponatraemialow blood sodium2.3%65

Top 30 of 542 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 100 drugs in the kinase inhibitor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 849,161 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 38.1% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 2,790 reports.

Drugs most often listed in the same reports

Other products listed in reports where Cabozantinib is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the kinase inhibitor class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Cabozantinib as a suspect or interacting product; reports listing it only as a concomitant medication (333) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.